Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 7/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | FABP4 | P15090 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6858314 | 0.88 | MAPT (0.48) | PPARGMAPTMAPK10MEN1KMT2A | |
| SCHEMBL6855595 | 0.76 | MAPT (0.48) | PPARGMAPTMAPK10FABP4LMNA | |
| SCHEMBL6858382 | 0.75 | PPARG (0.76) | PPARGMAPTMAPK10MEN1KMT2A | |
| SCHEMBL24482780 | 0.75 | CCR2 (0.65) | PPARGMAPTMAPK10MEN1KMT2A | |
| SCHEMBL6300362 | 0.75 | MAPT (0.57) | PPARGMAPTMAPK10MEN1KMT2A | |
| SCHEMBL6091286 | 0.74 | PPARG (0.51) | PPARGMAPTMAPK10 | |
| SCHEMBL6089789 | 0.73 | PPARG (0.48) | PPARG | |
| SCHEMBL24482668 | 0.73 | MAPT (0.55) | PPARGMAPTMAPK10MEN1KMT2A | |
| SCHEMBL24482672 | 0.73 | MAPT (0.55) | PPARGMAPTMAPK10MEN1KMT2A | |
| SCHEMBL24482670 | 0.73 | MAPT (0.53) | PPARGMAPTMAPK10MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6787651-B2 | 2-CARBOXY-SUBSTITUTED; TREATING OSTEOPENIA, OSTEOPOROSIS, CANCER, DIABETES AND ATHEROSCLEROSIS. | SMITHKLINE BEECHAM CORPORATION | 2004-09-07 | — | — | US | disclosed |
| US-20030087902-A1 | Substituted indoles, pharmaceutical compounds containing such indoles and their use as PPAR-gamma binding agents | SMITHKLINE BEECHAM CORPORATION | 2003-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087902-A1 | Substituted indoles, pharmaceutical compounds containing such indoles and their use as PPAR-gamma binding agents | PPARG, PPARA, PPARD | PPARG 1/4885MAPT 3447/4885MAPK10 1496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.